Capricor Therapeutics price target raised to $50 from $25 at Maxim

Maxim raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $25 and keeps a Buy rating on the shares. The firm cites the company’s top-line data from the HOPE-3 trial for Deramiocel ) in Duchenne muscular dystrophy meeting both the primary endpoint of PuL2.0 and the key secondary endpoint of left ventricular ejection fraction at statistically significant levels, as well as other measures, the analyst tells investors in a research note. The data demonstrated both skeletal and cardiac benefits, which tracked with prior observations in both the HOPE-2 phase 2 and HOPE-2 open-label extension, the firm added.